Fulcrum Therapeutics, Inc.
FULC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680581
In the last 90 days, Fulcrum Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 154 institutions reported holding it in 13F filings for Q2 2026, worth $291.3M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Fulcrum Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 110 | 116 | +6 |
| Shares | 50.6M | 60.4M | +9.78M (+19.3%) |
| Value | $368.5M | $172.2M | −$196.3M (−53.3%) |
New holders (27)
Institutions that held Fulcrum Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
Sold out (21)
Institutions that held Fulcrum Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Logos Global Management LP | 2,000,000 | $14.6M |
| TRV GP III, LLC | 1,962,202 | $14.3M |
| Deep Track Capital, LP | 768,607 | $5.60M |
| Sofinnova Investments, Inc. | 631,411 | $4.60M |
| Parkman Healthcare Partners LLC | 206,866 | $1.51M |
| International Biotechnology Trust PLC | 193,741 | $1.41M |
| Acuta Capital Partners, LLC | 185,000 | $1.35M |
| Schonfeld Strategic Advisors LLC | 106,600 | $776.0K |
| Man Group plc | 96,152 | $700.0K |
| J. Goldman & Co LP | 59,100 | $430.2K |
| Bridgeway Capital Management, LLC | 40,000 | $291.2K |
| Ameriprise Financial Inc | 20,994 | $153.0K |
| Alpine Global Management, LLC | 16,073 | $117.0K |
| SVB Financial Group | 22,422 | $22.4K |
| SOA Wealth Advisors, LLC. | 800 | $5.82K |
| Quantbot Technologies LP | 660 | $4.80K |
| Cutler Group LP | 500 | $3.00K |
| Signaturefd, LLC | 219 | $1.59K |
| US Bancorp | 153 | $1.11K |
| Parallel Advisors, LLC | 77 | $561 |
| Ellevest, Inc. | 19 | $138 |